Melbourne, June 24, 2009 (ABN Newswire) - Australian regenerative medicine company Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced successful results from the first five patients who underwent bone marrow transplantation with haematopoietic stem and progenitor cells expanded by the patented allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs).
The Phase I/II trial in up to 30 patients is being conducted by Mesoblast's US-based associated company Angioblast Systems Inc. at the University of Texas M. D. Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy. The trial is funded through a grant awarded by the United States National Institutes of Health (NIH).
Successful bone marrow reconstitution and engraftment was achieved in all five patients with haematologic malignancies who received MPC-expanded haematopoietic stem and progenitor cells from cord blood, with no cell-related adverse events. The median time to engraftment was 15 days, approximately two weeks faster than expected without MPC expansion.
The MPC product used in this trial is being developed under a United States Food and Drug Administration (FDA) orphan drug designation recently granted to Angioblast Systems Inc. for expanding haematopoietic stem and progenitor cell numbers in patients with haematologic malignancies.
Executive Director Professor Silviu Itescu said these initial results achieved with the Angioblast allogeneic MPCs were extremely encouraging.
"By significantly reducing the time to engraftment and increasing the overall success rate of an allogeneic bone marrow transplant, this technology has the potential to lower the risk of infections, bleeding, and death in critically ill patients with haematologic malignancies following chemotherapy," he said.
In view of the important nature of the unmet medical need, the Company will seek to obtain US FDA clearance to commence an accelerated Phase 3 program if subsequent patients in the trial continue to show enhanced bone marrow engraftment potential.
"This would represent a significantly shortened timetable to product commercialisation", added Professor Itescu.
About Orphan Drug Designation
Orphan drug designation is reserved for therapies which are being developed for conditions affecting up to 200,000 patients annually in the US, and allows for an accelerated review process by the FDA, seven-year market exclusivity in the US upon obtaining marketing authorisation, tax benefits, and exemption from user fees.
The Phase I/II trial in up to 30 patients is being conducted by Mesoblast's US-based associated company Angioblast Systems Inc. at the University of Texas M. D. Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy. The trial is funded through a grant awarded by the United States National Institutes of Health (NIH).
Successful bone marrow reconstitution and engraftment was achieved in all five patients with haematologic malignancies who received MPC-expanded haematopoietic stem and progenitor cells from cord blood, with no cell-related adverse events. The median time to engraftment was 15 days, approximately two weeks faster than expected without MPC expansion.
The MPC product used in this trial is being developed under a United States Food and Drug Administration (FDA) orphan drug designation recently granted to Angioblast Systems Inc. for expanding haematopoietic stem and progenitor cell numbers in patients with haematologic malignancies.
Executive Director Professor Silviu Itescu said these initial results achieved with the Angioblast allogeneic MPCs were extremely encouraging.
"By significantly reducing the time to engraftment and increasing the overall success rate of an allogeneic bone marrow transplant, this technology has the potential to lower the risk of infections, bleeding, and death in critically ill patients with haematologic malignancies following chemotherapy," he said.
In view of the important nature of the unmet medical need, the Company will seek to obtain US FDA clearance to commence an accelerated Phase 3 program if subsequent patients in the trial continue to show enhanced bone marrow engraftment potential.
"This would represent a significantly shortened timetable to product commercialisation", added Professor Itescu.
About Orphan Drug Designation
Orphan drug designation is reserved for therapies which are being developed for conditions affecting up to 200,000 patients annually in the US, and allows for an accelerated review process by the FDA, seven-year market exclusivity in the US upon obtaining marketing authorisation, tax benefits, and exemption from user fees.
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.
Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.
The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.
Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.
|
||
|
 |
Related Companies |
>>>       Mesoblast Limited |
| |
Related Industry Topics: |
Biotech | Financial General | Health & Pharm General | |
| |
This Page Viewed: (Last 7 Days: 20) (Last 30 Days: 110) (Since Published: 14750) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
AJAX UNION |
|||
|
|||
Companies in the News
ABN Newswire on iPhone/iPad
|
| Download from Apple |
Mobile Video TV
|
||
|
||
){kind=link}